Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. (Nasdaq: COCP) on July 10, 2025. The report discloses a material event under Item 7.01 (Regulation FD Disclosure) regarding the company's clinical development pipeline.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific corporate event rather than periodic financial results.
Material Changes and Events
- Scientific Presentation: The Company announced that its broad-spectrum protease inhibitor, CDI-988, will be featured in an oral presentation at the 9th International Calicivirus Conference.
- Disclosure Status: The information, including the accompanying press release (Exhibit 99.1), is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or specific risk factors beyond the standard disclaimer regarding the non-filed status of the press release. The primary focus is the upcoming scientific presentation of CDI-988.
Investor Verification Checklist
- Verify the date and specific content of the oral presentation at the 9th International Calicivirus Conference.
- Review the full text of the press release provided as Exhibit 99.1 for details on CDI-988 data.
- Confirm the current clinical development status of CDI-988 in subsequent filings or investor presentations.